During the last years a considerable therapeutic progress in melanoma patients with the RAF V600E mutation via RAF/MEK pathway inhibition and immuno-therapeutic modalities has been witnessed. However, the majority of patients relapse after therapy. Therefore, a deeper understanding of the pathways driving oncogenicity and metastasis of melanoma is of paramount importance. In this review, we summarize microRNAs modulating tumor growth, metastasis, or both, in preclinical melanoma-related in vivo models and possible clinical impact in melanoma patients as modalities and targets for treatment of melanoma. We have identified miR-199a (ApoE, DNAJ4), miR-7-5p (RelA), miR-98a (IL6), miR-219-5p (BCL2) and miR-365 (NRP1) as possible targets to be scrutinized in further target validation studies.

中文翻译：

---

微小RNA促进皮下黑色素瘤临床前体内模型的生长和转移。

在过去的几年中，通过RAF / MEK途径抑制和免疫治疗方法对RAF V600E突变的黑素瘤患者进行了可观的治疗。但是，大多数患者在治疗后复发。因此，更深入了解驱动黑色素瘤致癌性和转移的途径至关重要。在这篇综述中，我们总结了在临床前黑色素瘤相关的体内模型中调节肿瘤生长，转移或两者的微小RNA，以及作为黑色素瘤治疗的方式和目标的对黑色素瘤患者的潜在临床影响。我们确定了miR-199a（ApoE，DNAJ4），miR-7-5p（RelA），miR-98a（IL6），miR-219-5p（BCL2）和miR-365（NRP1）是可能要研究的靶标进一步的目标验证研究。